Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 2Unknown 1Terminated 1Approved for marketing 1

Sponsor Class

OTHER 5

Study Type

Interventional 3Observational 1Expanded_access 1

Sponsor

Cancer Type

Sarcoma 6Lymphoid 6Other hematologic neoplasm 5Other 2Genitourinary 1

Conditions

Osteosarcoma 3Renal Insufficiency 2Lymphoma 2Leukemia 2Hematologic Neoplasms 2Water Intoxication 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Acute Kidney Injury 1

Interventions

Cytarabine 905Cyclophosphamide 898fludarabine 524venetoclax 487fludarabine phosphate 468Azacitidine 459Rituximab 431Methotrexate 419Etoposide 320Filgrastim 299Busulfan 296Dexamethasone 286Vincristine 285Daunorubicin 283Peripheral Blood Stem Cell Transplantation 258Whole-Body Irradiation 243Mycophenolic Acid 232Decitabine 229Granulocyte Colony-Stimulating Factor 227Tacrolimus 220Imatinib Mesylate 211Idarubicin 204Melphalan 202Cyclosporine 182Doxorubicin 177Radiotherapy 169Prednisone 163Dasatinib 163Mitoxantrone 161Lenalidomide 160

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
glucarpidase × Other hematologic neoplasm × Clear all
NCT05899751 2024-05-10

Retrospective Registry Study of Patients With Cancer Treated With High-dose Methotrexate

BTG International Inc.

Unknown
1,000 enrolled
GenitourinaryOther hematologic neoplasmSarcoma

Osteosarcoma, Water Intoxication, Hematologic Neoplasms, Acute Kidney Injury, Drug-Related Side Effects and Adverse Reactions

NCT00634504 2022-06-06

LVPK

BTG International Inc.

Phase 1 Completed
20 enrolled 9 charts
LymphoidOther hematologic neoplasmSarcoma

Leukemia, Lymphoma, Osteosarcoma, Renal Insufficiency

NCT01305655 2018-09-28

NOPHOCPG2

Nordic Society for Pediatric Hematology and Oncology

Phase 3 Completed
47 enrolled 5 charts
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00481559 2014-01-17

Treatment Protocol of Voraxaze for Patients Experiencing or at Risk of Methotrexate Toxicity

BTG International Inc.

Approved for marketing
LymphoidOther hematologic neoplasmSarcoma

Leukemia, Lymphoma, Neoplasms, Osteosarcoma, Renal Insufficiency

NCT00424645 2012-12-06

Voraxaze for Delayed Methotrexate Clearance

M.D. Anderson Cancer Center

Phase 1/2 Terminated
3 enrolled 2 charts
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡